The Insulin-like Growth Factor System and Its Receptors: A Potential Novel Anticancer Target

Overview

Journal Biologics

Date 2009 Aug 27

PMID 19707463

Citations 1

Authors

Colin R Lindsay

Tr Jeffry Evans

Affiliations

Soon will be listed here.

Abstract

The current generation of novel anticancer therapies that are in preclinical and clinical development are based on exploiting our increasing understanding of the molecular and cellular basis of cancer development and progression. Accelerated rates of cell division and proliferation have been postulated to predispose to the development of malignant disease. The insulin-like growth factor (IGF) signaling system has an important physiological role in regulating cellular proliferation and apoptosis. This function has led to considerable interest in its relevance to neoplasia over the last decade. In this review, we give an overview of the IGF system physiology, discuss the epidemiological significance of IGF signaling and neoplasia, and review the preclinical and clinical studies in targeting IGF receptors as cancer therapies.

Citing Articles

Profiling microRNAs in lung tissue from pigs infected with Actinobacillus pleuropneumoniae.

Podolska A, Anthon C, Bak M, Tommerup N, Skovgaard K, Heegaard P BMC Genomics. 2012; 13:459.

PMID: 22953717 PMC: 3465251. DOI: 10.1186/1471-2164-13-459.

References

Ma , Giovannucci , Pollak , Stampfer . RESPONSE: Re: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3. J Natl Cancer Inst. 1999; 91(23):2052. DOI: 10.1093/jnci/91.23.2052. View

Dunn S, Ehrlich M, Sharp N, Reiss K, Solomon G, Hawkins R . A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 1998; 58(15):3353-61. View

Pollak M, Schernhammer E, Hankinson S . Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004; 4(7):505-18. DOI: 10.1038/nrc1387. View

Michels K, Xue F, Terry K, Willett W . Longitudinal study of birthweight and the incidence of breast cancer in adulthood. Carcinogenesis. 2006; 27(12):2464-8. DOI: 10.1093/carcin/bgl105. View

Yee D . Targeting insulin-like growth factor pathways. Br J Cancer. 2006; 94(4):465-8. PMC: 2361182. DOI: 10.1038/sj.bjc.6602963. View

Nahta R, Yuan L, Zhang B, Kobayashi R, Esteva F . Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005; 65(23):11118-28. DOI: 10.1158/0008-5472.CAN-04-3841. View

Dufourny B, Alblas J, van Teeffelen H, van Schaik F, van der Burg B, Steenbergh P . Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem. 1998; 272(49):31163-71. DOI: 10.1074/jbc.272.49.31163. View

Federici M, Porzio O, Zucaro L, Fusco A, Borboni P, Lauro D . Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues. Mol Cell Endocrinol. 1997; 129(2):121-6. DOI: 10.1016/s0303-7207(97)04050-1. View

Zhang L, Zhou W, Velculescu V, Kern S, Hruban R, Hamilton S . Gene expression profiles in normal and cancer cells. Science. 1997; 276(5316):1268-72. DOI: 10.1126/science.276.5316.1268. View

10.

Strohm O, Osterziel K, Dietz R . Insulin-like growth factor-I and risk of breast cancer. Lancet. 1998; 352(9126):489. DOI: 10.1016/s0140-6736(05)79227-8. View

11.

Rowinsky E, Youssoufian H, Tonra J, Solomon P, Burtrum D, Ludwig D . IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res. 2007; 13(18 Pt 2):5549s-5555s. DOI: 10.1158/1078-0432.CCR-07-1109. View

12.

Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T . Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol. 1994; 14(6):3604-12. PMC: 358728. DOI: 10.1128/mcb.14.6.3604-3612.1994. View

13.

Tornell J, Rymo L, Isaksson O . Induction of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice. Int J Cancer. 1991; 49(1):114-7. DOI: 10.1002/ijc.2910490121. View

14.

Cohen B, Baker D, Soderstrom C, Tkalcevic G, Rossi A, Miller P . Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. 2005; 11(5):2063-73. DOI: 10.1158/1078-0432.CCR-04-1070. View

15.

Giovannucci E, Pollak M, Liu Y, Platz E, Majeed N, Rimm E . Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev. 2003; 12(2):84-9. View

16.

Khandwala H, McCutcheon I, Flyvbjerg A, Friend K . The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000; 21(3):215-44. DOI: 10.1210/edrv.21.3.0399. View

17.

BAXTER R . Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000; 278(6):E967-76. DOI: 10.1152/ajpendo.2000.278.6.E967. View

18.

Morgillo F, Kim W, Kim E, Ciardiello F, Hong W, Lee H . Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res. 2007; 13(9):2795-803. DOI: 10.1158/1078-0432.CCR-06-2077. View

19.

Palmqvist R, Hallmans G, Rinaldi S, Biessy C, Stenling R, Riboli E . Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut. 2002; 50(5):642-6. PMC: 1773192. DOI: 10.1136/gut.50.5.642. View

20.

Peyrat J, Bonneterre J, Hecquet B, Vennin P, Louchez M, Fournier C . Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer. 1993; 29A(4):492-7. DOI: 10.1016/s0959-8049(05)80137-6. View